HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's FY 1996 spending bill passes unamended by House panel; budget resolution assumes AHCPR elimination.

Executive Summary

HOUSE APPROPRIATIONS REPORTS OUT FDA FY 1996 SPENDING BILL WITH NO CHANGES after a one-day committee mark-up on June 27. The FDA portion of the Agriculture appropriations bill was not debated, and no amendments to the provision were introduced.

You may also be interested in...



AHRQ Stepping Up Cost-Effectiveness Research; Says Key Is Openness

The Agency for Healthcare Research & Quality is ready to take on a new role in cost-effectiveness research, Director Carolyn Clancy, MD, said at an AHRQ National Advisory Council meeting Nov. 7

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Latest Headlines
See All
UsernamePublicRestriction

Register

PS026443

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel